ProCE Banner Activity

Nonsteroidal Mineralocorticoid Receptor Antagonist in Type 2 Diabetes–Associated Chronic Kidney Disease

Slideset Download

A leading expert provides an overview of the cardiorenal benefits of finerenone in patients with type 2 diabetes and chronic kidney disease.

Released: July 07, 2022

Expiration: July 06, 2023

Share

Faculty

Joshua J. Neumiller

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Vice Chair & Allen I. White Distinguished Professor
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, Washington

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by independent educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Boehringer Ingelheim and Eli Lilly

Faculty Disclosure

Primary Author

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Vice Chair & Allen I. White Distinguished Professor
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, Washington

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, has disclosed that he has received consulting fees from Bayer, Dexom, Novo Nordisk, and Sanofi.